Breaking news

Rocket.new Secures $15 Million to Redefine AI-Driven App Development

by THEFUTURE.TEAM

September 23, 2025

Overview Of Rocket.new’s Bold Mission

Indian startup Rocket.new, an innovative force in AI-powered app development, has successfully raised $15 million in a seed funding round led by Salesforce Ventures. The funding round, which saw participation from Accel and Together Fund, marks a significant step forward as Rocket.new challenges competitors like Lovable, Cursor, and Bolt. By offering a platform that creates full, production-ready applications through natural-language prompts, Rocket.new is moving beyond the rapid prototyping that has characterized the current wave of vibe-coding tools.

Impressive Growth And Market Traction

Since its beta launch in June, the platform has grown its user base to over 400,000 individuals across 180 countries, including more than 10,000 paying subscribers. With annual recurring revenue already at $4.5 million, CEO Vishal Virani has set ambitious targets—projecting $20–$25 million by the end of the year and reaching $60–$70 million by June next year. These rapid achievements underscore the platform’s potential, drawing the attention of leading companies such as Meta, PayPal, KPMG, PwC, and Times Internet.

Follow THE FUTURE on LinkedIn, Facebook, Instagram, X and Telegram

Innovative Architecture And Superior User Experience

The Rocket.new platform distinguishes itself by integrating large language models from Anthropic, OpenAI, and Google’s Gemini with its own deep learning systems. Leveraging proprietary datasets from its previous venture DhiWise, Rocket.new has built an architecture that offers a comprehensive solution for production-ready applications. Although initial app generation takes approximately 25 minutes—longer than some competitors—the platform’s robust output is designed to include all essential modules, delivering a superior user experience that appeals to serious application developers.

Strategic Funding And Future Growth

Founder and CEO Vishal Virani, along with co-founders Rahul Shingala and Deepak Dhanak, have positioned Rocket.new to spearhead a shift in how organizations approach app development. The startup aims to develop a full-fledged agentic system capable not only of building apps and websites but also of conducting competitive research and product development, potentially eliminating the need for traditional product management roles. With around 58 team members based out of Surat—and plans to double its engineering and product staff in India—the company is set to broaden its presence, especially in pivotal markets like the U.S., where it has already secured 26% of its revenue.

Monetization Strategy And Global Reach

The company employs a freemium model, offering a free trial capped at one million tokens, with continued access available through monthly subscriptions starting at $25 for five million tokens. This pricing structure is designed to foster enterprise-level usage while maintaining healthy gross margins, with ambitions to improve these figures further in the coming months.

Conclusion

Rocket.new’s fresh infusion of capital, impressive early traction, and strategic market positioning not only set it apart from its rivals but also signal a significant evolution in AI-assisted app development. As it prepares to refine its go-to-market strategies and invest further in proprietary R&D, Rocket.new is poised to become a cornerstone platform for organizations seeking to harness artificial intelligence for production-grade applications.

The Future Forbes Realty Global Properties

Blood Proteins May Signal Prostate Cancer Risk More Than 15 Years Before Diagnosis

by THEFUTURE.TEAM

October 27, 2026

Distinctive proteins in men’s blood may offer clues to prostate cancer risk more than 15 years before a diagnosis, according to research from the University of Oxford. The findings could help scientists better understand why some prostate cancers become aggressive while others grow slowly and never cause serious harm.

Researchers analyzed blood samples from 2,555 men collected between 1992 and 2000. Of those participants, 982 were later diagnosed with prostate cancer; the remaining 1,573 served as a comparison group. The team measured more than 6,000 proteins in the samples, which had been collected years—and, in some cases, more than 15 years—before diagnosis.

Follow THE FUTURE on LinkedIn, Facebook, Instagram, X and Telegram

Protein Patterns Were Linked To Different Risks

The analysis identified proteins associated with prostate cancer risk overall, as well as proteins linked specifically to more aggressive or fast-growing forms of the disease. Higher levels of certain immune-system proteins, including GZMK and ANXA2, were associated with a lower long-term risk.

“Finding proteins linked to known prostate cancer driver genes in blood collected years before diagnosis gives us new insights into the earliest stages of the disease,” said Karl Smith-Byrne, the study’s corresponding author at Oxford.

The results, published in European Urology, are significant because prostate cancer is not a single, uniform disease. Many tumors grow slowly and may never threaten a patient’s health, while others progress rapidly and can be life-threatening. A clearer way to distinguish between these outcomes could eventually help improve how clinicians assess risk.

Promising Findings, Not A Screening Test

The researchers stressed that the protein patterns are not ready to be used as a screening test. The associations need further validation before they can inform clinical decisions, and the study does not establish that the proteins cause cancer or that measuring them can predict an individual’s outcome.

“Ultimately, we hope this will help us understand the biology of aggressive prostate cancer and identify markers that could improve how we assess risk in the future,” said first author Zhe Huang, a postdoctoral epidemiologist at Oxford Population Health.

Research Could Point To New Prevention Strategies

Prostate cancer is the most commonly diagnosed cancer among men in the European Union and the second most common worldwide, after lung cancer. In the EU, approximately 330,000 cases are diagnosed and 75,000 men die from the disease each year.

By identifying biological signals that appear long before diagnosis, the research may help scientists investigate the pathways involved in aggressive disease. Smith-Byrne said that, alongside existing and future genetic evidence, the findings could help reveal pathways that might ultimately be targeted to prevent aggressive prostate cancer.